Publications by authors named "Taotao Yin"
Article Synopsis
- Ovarian cancer, the deadliest gynecological cancer, faces major treatment obstacles, particularly with PARP inhibitors (PARPi) for BRCA1/2-mutated tumors, as resistance to these drugs is a significant challenge.
- An experiment developed a PARPi-resistant cell line (A2780-OlaR), revealing increased levels of CYP1B1, and demonstrated that manipulating its expression affected responses to Olaparib, the PARP inhibitor.
- The study concludes that CYP1B1 plays a crucial role in PARPi resistance, showing how chromatin accessibility impacts drug effectiveness and suggesting new strategies to fight ovarian cancer.
The challenge of methotrexate (MTX) resistance among low-risk gestational trophoblastic neoplasia (GTN) patients has always been prominent. Despite the International Federation of Gynaecology and Obstetrics (FIGO) score of 0-4 patients comprising the majority of low-risk GTN patients, a comprehensive exploration of the prevalence and risk factors associated with MTX resistance has been limited. Therefore, we aimed to identify associated risk factors in GTN patients with a FIGO score of 0-4.
View Article and Find Full Text PDFBackground: Cervical cancer is characterized by a complex immunosuppressive tumor microenvironment (TME). Disulfidptosis is a recently identified form of programmed cell death that has emerged as a crucial factor in tumorigenesis. However, the research on the specific involvement of disulfidptosis within the TME is still in its early stages.
View Article and Find Full Text PDF